Women's Health

On Women Pharmacist Day on October 12, a panel discussion webcast consisting of leading women in pharmacy discussed the importance of recognizing the impact of women on the pharmacy landscape and the history of women in the field.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Top news of the week from Pharmacy Times.

Women found to have worse outcomes after a first heart attack than men.

On Women Pharmacists Day, 5 industry leaders discuss work-life balance, job advancement, and mentorship.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Pharmacy Times spoke with Lisa King, founder of the Fulfilled Pharmacist, about the importance of women in the pharmacy field and Women Pharmacist Day.

In recognition of Women Pharmacist Day, a panel of experts discuss the history and significance of women in pharmacy, including demographics, changes in policy and culture, tips for pharmacist moms and different career paths.

Study shows that human papillomavirus vaccine mandates do not increase coverage or vaccination rates among vulnerable communities.

In an upcoming webcast to celebrate #WomenPharmacistDay, female leaders in pharmacy will discuss the importance of recognizing the impact of women on the pharmacy landscape.

Women who had longer reproductive periods during their lifetimes were found to have a greater risk of dementia in older age compared with those who had shorter reproductive periods.

Women with 2 or more moderate to severe menopause symptoms are at a heightened risk of cardiovascular disease and stroke.

The study suggests that babies born to mothers infected with the virus generally do well 6 to 8 weeks after birth.

Lower birth weight babies may not be able to metabolize medication as efficiently as normal weight babies.

Lactic acid, citric acid, and potassium bitartrate is a prescription combination, non-hormonal contraceptive gel found to be 86.3% effective with typical use.

Post-menopausal women are at a heightened risk of Alzheimer disease.

Despite contrary studies, new evidence indicates premenopausal women fair better after a heart attack than men.

Metabolic studies have found that although pregnancy reduces the body’s sensitivity to insulin, lactation may restore it.

Abdominal weight gain during the postmenopausal period is associated with the use of antidepressants, beta-blockers, and insulin during the menopause transition.

Women comprise more than 60% of pharmacy graduates, yet gender gaps still exist in pharmacy ownership, school deanships, and other leadership positions.

New ruling means up to 126,400 women of childbearing age may need to pay out-of-pocket for birth control.

In addition to finding that depression affects up to 70% of women transitioning into menopause, investigators have also identified the greatest risk factors.

Gardasil 9 approved for the prevention of oropharyngeal cancer and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.

Oriahnn is the first FDA-approved nonsurgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

The FDA recently announced its approval of a vaginal gel that acts as a method of contraception for women. It is the first non-hormonal, vaginal pH regulator contraceptive to be approved by the FDA.

The authors concluded that costs were significantly higher for women with migraines than men and that costs resulting from migraine treatment increased as the patients got older.

Suzanne Soliman, PharmD, BCMAS, Founder and President of Pharmacist Moms, explains why there is a still a need for women to hold positions of leadership in pharmacy, despite the strides in recent years.

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.

Although 62% of the first professional degrees in pharmacy were awarded to women in 2017-2018,1 there are only about half as many female pharmacy owners as there are women graduating from pharmacy school.